Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sirolimus topical gel NPC-12Y

A topical gel formulation containing the macrolide sirolimus (rapamycin), with potential anti-proliferative activity. Upon topical administration of sirolimus topical gel NPC-12Y, sirolimus is internalized by the affected cells in the skin. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus-FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR) and the mTOR-mediated signaling pathways, which reduces cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:topical sirolimus gel NPC-12Y
Code name:NPC 12Y
NPC-12Y
NPC12Y
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search